Knight Therapeutics Inc
TSX:GUD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
CA |
|
Neurogene Inc
NASDAQ:NGNE
|
US |
|
Impax Asset Management Group PLC
LSE:IPX
|
UK |
|
O
|
Opticept Technologies AB
STO:OPTI
|
SE |
|
C
|
China Star Food Group Ltd
SGX:42W
|
SG |
|
ANZ Group Holdings Ltd
OTC:ANZGF
|
AU |
Wall Street
Price Targets
GUD Price Targets Summary
Knight Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for GUD is 8.51 CAD with a low forecast of 6.21 CAD and a high forecast of 11.55 CAD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is GUD's stock price target?
Price Target
8.51
CAD
According to Wall Street analysts, the average 1-year price target for GUD is 8.51 CAD with a low forecast of 6.21 CAD and a high forecast of 11.55 CAD.
What is Knight Therapeutics Inc's Revenue forecast?
Projected CAGR
7%
For the last 10 years the compound annual growth rate for Knight Therapeutics Inc's revenue is 84%. The projected CAGR for the next 3 years is 7%.
What is Knight Therapeutics Inc's Operating Income forecast?
Projected CAGR
89%
The compound annual growth rate of Knight Therapeutics Inc's operating income for the next 3 years is 89%.
